Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(−) advanced breast cancer: results from BOLERO-2

BACKGROUND: The current analysis was performed to evaluate the impact of PIK3CA hotspot mutations on everolimus efficacy in BOLERO-2 participants, using cell-free DNA (cfDNA) from plasma samples collected at the time of patient randomisation. METHODS: PIK3CA H1047R, E545K, and E542K mutations in pla...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Moynahan, Mary Ellen, Chen, David, He, Wei, Sung, Patricia, Samoila, Aliaksandra, You, Daoqi, Bhatt, Trusha, Patel, Parul, Ringeisen, Francois, Hortobagyi, Gabriel N, Baselga, Jose, Chandarlapaty, Sarat
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2017
Matèries:
Translational Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355930/
https://ncbi.nlm.nih.gov/pubmed/28183140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.25
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars